With a recorded 23,000+ companies disclosing through CDP in 2023, disclosing data on environmental impact is now a business norm. TFS’s data will be added to the most comprehensive inventory of self-reported environmental data in the world – helping to drive action through greater transparency.  

Kajsa Petersson, Internal Communications, Culture and Sustainability Director at TFS, said, “We are honored to receive CDP recognition for our commitment to environmental transparency. Our dedication to disclosure stems from our commitment to delivering high-quality clinical research responsibly, fostering the long-term success of the healthcare industry – providing life-saving care to patients globally.”  

By disclosing through CDP, TFS is prepared to respond to the increasing demand for environmental transparency from financial institutions, customers, and policymakers. In its disclosure, TFS shared information on past, current, and future strategies for identifying and addressing the company’s environmental impact. 

“We believe that implementing sustainable strategies is an integral part of our business activities. Having our efforts recognized by CDP motivates us to continue on the path to a greener, healthier, more sustainable future for all,” said Patrik Darsund, Chief People Officer, at TFS.

TFS showcases its commitment to environmental sustainability by leveraging advanced, automated data collection platforms and intelligent travel emission tracking software, highlighting its proactive stance. Already engaged in setting science-based emissions targets through the Science Based Targets initiative (SBTi) for 2025, the company aims at enhancing sustainable procurement, investing in renewable energy, and optimizing energy-efficient operations. This commitment is further evidenced by its consistent Silver Rating from EcoVadis, placing it within the top 8% of 1.6 million companies in 2023, marking a notable rise from the top 15% in 2022. 

Sherry Madera, CDP’s Chief Executive Officer, stated, “With over 23,000 businesses disclosing through CDP this year, it is clear that sustainability, and the data that underpins it, is an essential part of long-term success in the business community. Disclosure works, and today we should take a short pause to celebrate the dedication to transparency and accountability shown by TFS HealthScience reporting through CDP this year. By sharing their environmental data with CDP, TFS HealthScience is continuing, an environmental journey that will contribute to keeping that future in sight.” 

The full list of companies disclosing through CDP can be accessed here: https://www.cdp.net/en/responses 

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology.  

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com 

About CDP

CDP is a global non-profit that runs the world’s environmental disclosure system for companies, cities, states, and regions. Founded in 2000, CDP works with more than 740 financial institutions with over US$137 trillion in assets. They have pioneered using capital markets and corporate procurement to motivate companies to disclose their environmental impacts, reduce greenhouse gas emissions, safeguard water resources, and corporate procurement to motivate companies to disclose their environmental impacts, reduce greenhouse gas emissions, safeguard water resources, and protect forests. Over 25,000 organizations around the world disclosed data through CDP in 2023, with more than 23,000 companies – including listed companies worth two-thirds of global market capitalization – and over 1,100 cities, states, and regions. 

Fully TCFD aligned, CDP holds the largest environmental database in the world, and CDP scores are widely used to drive investment and procurement decisions towards a zero carbon, sustainable, and resilient economy. CDP is a founding member of the Science Based Targets initiative, We Mean Business Coalition, The Investor Agenda, and the Net Zero Asset Managers initiative. Visit ww.cdp.net to learn more

Media Contact  

Emma Primon 
Executive Director, Marketing & Communications
+1 (908) 331.5463
Email

The post TFS HealthScience Earns Elevated Score from Carbon Disclosure Project (CDP)  appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

The APAC region presents a promising landscape for clinical research, with a diverse patient population encompassing various ethnicities, demographics, and medical conditions. According to the Clinical Leader, the APAC CRO market is expected to grow to US$12 billion by 2025. TFS recognizes the potential to contribute significantly to advancing medical knowledge and improving patient outcomes in this vibrant and growing market. 

Dr. Bassem Saleh, Chief Executive Officer at TFS, expressed his enthusiasm for the expansion, stating, “As we extend our footprint into the APAC region, Australia emerges as a strategic focal point for establishing operations in all our business units, including Ophthalmology, Dermatology, Neurology, Oncology, and Strategic Resourcing. Australia’s expanding market aligns perfectly with our vision for growth and innovation. This expansion enables us to better integrate into the APAC region and strengthens our commitment to delivering unparalleled clinical research solutions to our global network.” 

While the company has previously offered geographical coverage through consultants and partner CROs in the region, this expansion represents a commitment to developing a dedicated operational base, expanding their site network, and patients’ access to clinical trials. Starting with Australia, TFS has plans for further growth into other countries in the APAC region, complementing existing partnerships to cater to customer needs globally. 

TFS’s expansion into the APAC region enhances the company’s partnership capabilities, offering unique advantages to sponsors and partners. This strategic move not only broadens access to diverse patient populations and cutting-edge technologies but also leverages streamlined regulatory environments for faster, more efficient trial execution. By integrating this with its commitment to cultural diversity and global collaboration, TFS underlines its role as a leading CRO partner, equipped to navigate the complexities of global clinical research with precision and cultural sensitivity. 

About TFS HealthScience  

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800+ professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology. 

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com 

Media Contact  

Emma Primon 
Executive Director, Marketing & Communications
+1 (908) 331.5463
Email

The post TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

CHARLOTTE, N.C. (Dec. 11, 2023) – Premier, Inc.’s PINC AI Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.  

The partnership will combine TFS’ capabilities, systems, and clinical development expertise with PAS’ AI-enabled technology and comprehensive healthcare database. The collaboration will expedite site and patient enrollment, reduce trial costs, accelerate the journey to commercialization, and ensure equitable access to groundbreaking medical solutions across diverse patient populations. 

Eighty percent of all trials face premature termination or significant delays due to recruitment challenges – and marginalized populations, including Black and Hispanic individuals, remain historically underrepresented.  

Leveraging comprehensive real-world data (RWD) and AI-enabled tools from PAS, TFS will gain enhanced capabilities to assess site suitability on a larger scale and focus on appropriate patient populations, investigator availability, therapeutic areas expertise and historical clinical trial performance metrics. This data-driven approach has already enabled PAS-supported trials to improve recruitment by 1800 percent and triple enrollment compared to baseline projections – significantly reducing enrollment periods and costs. 

“The PAS-TFS partnership will bring the advantages of high-quality RWD/RWE and the benefits of AI-enabled technology to trial sponsors, investigators and life sciences entities worldwide,” said Denise Juliano, Group Vice President of Life Sciences at Premier. “Our combined strengths will help enhance data analysis, provide trial designs that are both diverse and equitable, advance early disease detection and reduce disparities with aim to advance global health equity.” 

Dr. Bassem Saleh, Chief Executive Officer at TFS, emphasizes the global impact of the collaboration: “Technology, including AI, will help accelerate clinical research through efficient clinical trial designs, synthetic arms, and faster patient identification and recruitment. Working with PAS will open new avenues for innovative clinical trials in Europe and the U.S., benefiting biotech, pharma and medical device companies across various phases and real-world evidence studies and ensuring more inclusive and patient-centric research.”   

The PAS-TFS partnership has plans for implementation in multiple studies per year across all therapeutic areas and indications. Data-driven designs will enable sponsors to integrate decentralized approaches with an emphasis on remote health and in-home patient monitoring options using mobile apps and wearables, helping lower overall trial costs. 

This strategic collaboration is set to further enable TFS’s expansion in the U.S. and enhance PINC AI’s global influence, especially in the European market, leveraging TFS’s extensive network. By uniting their capabilities, PAS and TFS are committed to driving forward innovation in clinical research and offering efficient solutions that prioritize patient health outcomes and equity.  

About TFS HealthScience
TFS HealthScience is a global clinical Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions. 

About PINC AI Applied Sciences (PAS)
PAS is a trusted leader in accelerating healthcare improvement through services, data and scalable solutions, spanning the continuum of care and enabling sustainable innovation and rigorous research. These services and RWD are valuable resources for the pharmaceutical, device and diagnostic industries, academia, federal and national healthcare agencies, as well as hospitals and health systems. Since 2000, PAS researchers have produced more than 1,000 publications which appear in 264 scholarly, peer-reviewed journals, covering a wide variety of topics, and conduct population-based analyses of drugs, devices, treatments, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes. 

About the PINC AI Platform
PINC AI is the technology and services platform of Premier, Inc. (NASDAQ: PINC). With more than 20 years’ worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 2.7 billion hospital outpatient and clinic encounters and 177 million physician office visits, the PINC AI platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI incorporates the 100 Top Hospitals ® Program that inspires hospital and health system leaders to pursue higher performance and deliver added value to their patients and communities. PINC AI offerings rely on advanced analytics to identify improvement opportunities; support award-winning Strategic Collaboratives for value-based care, maternal and infant health, workforce innovation, and health equity; and consulting services for clinical and operational design, and workflow solutions to hardwire sustainable change. The PINC AI platform is also the data engine powering Premier’s newest brands – Remitra® and Contigo Health®. With a leading network of provider organizations, the PINC AI platform accelerates ingenuity and serves as a large-scale innovation catalyst in healthcare. PINC AI offerings and capabilities can be followed on X (formerly Twitter) and LinkedIn. 

Contact: Public_Relations@premierinc.com 

The post Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience Will Partner to Revolutionize Clinical Trials appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Medidata Detect will help data managers and clinical operations teams improve patient safety, data quality oversight, and risk management. By analyzing and harmonizing data from many sources in a single location and identifying patterns and discrepancies, this solution offers a complete view of clinical trials and drives efficient workflows – allowing TFS to better focus on patients and clients.

“In spearheading our adoption of Medidata Detect, we’re not only reinforcing our commitment to data quality and patient safety, but we’re also embracing a pivotal enhancement to our existing technology stack,” said Michael Mendoza, TFS Executive Director of eClinical Technology and Biometrics. “Our partnership with Medidata now extends beyond the realms of Rave® EDC, CTMS, and eTMF, illustrating a significant step in our long-term strategy to advance clinical trial efficiency through innovation.”

“We are thrilled to be the first CRO implementing Medidata’s Detect platform, which addresses many data inefficiencies the industry experiences today,” said TFS Chief Executive Officer, Dr. Bassem Saleh. “Using a centralized data management system will enhance data quality, risk management, and decision-making, fast-tracking clinical trials for clients and the availability of drugs for patients.”

Detect identifies and addresses both known and unexpected risks in trials, prompting corrective actions that prevent study delays and submission failures. As a cornerstone of the risk-based quality management approach to clinical development, this innovative solution streamlines data management by eliminating breakpoints and will expand TFS HealthScience’s data access across platforms.

“At Medidata, we’re collaborating with our 2,300+ global customers to accelerate clinical trials by developing new, scalable data experiences that improve quality, maximize efficiency, and better support patients,” said Tom Doyle, Chief Technology Officer, Medidata. “Medidata Detect will give TFS HealthScience a competitive advantage with AI-driven insights and task automation that reduce the time to high-quality data and bring operational teams closer, eliminating redundancies and aligning processes across the organization.”

This partnership solidifies TFS as a leading and innovative clinical research organization focused on accelerating safety review cycles and helping biotechnology and pharmaceutical companies bring life-changing products, therapies, and medications to market as quickly as possible. “This integration showcases our dedication to leveraging cutting-edge technology for clinical excellence. It’s a testament to the proactive strides TFS is taking to grow technologically and further solidify our full partnership with Medidata,” highlighted Mendoza.

About TFS HealthScience
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together more than 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions.

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.

About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

The post TFS HealthScience Becomes First CRO to Adopt Medidata Detect, Improving Data Sharing Efficiency and Product Development appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Aligning with top-tier governance and social frameworks, TFS demonstrates a robust commitment to the pillars of the Environmental, Social, and Governance (ESG) model. These initiatives underscore the organization’s dedication to regulatory adherence, data protection, workforce diversity, and professional growth.

Among the 1.6 million companies evaluated by EcoVadis across various sectors worldwide, TFS now ranks within the distinguished top 8%, a significant jump from its previous position in the top 15% in 2022. The improved score reflects TFS’s progressive strategies and performance in environmental efforts, labor and human rights, ethics, and sustainable procurement.

Kajsa Petersson, Director of Internal Communications, Culture, and Sustainability for TFS, states, “This rating is a testament to TFS’s commitment to transparent and ethical behavior in building a successful, trusted company delivering quality clinical research for improved healthcare outcomes in a socially responsible and sustainable manner. Having our efforts recognized by EcoVadis indicates that we are on the right path and serves as a tremendous encouragement to continue on that path to a greener, healthier, more sustainable future for us all.”

Learn more about how TFS HealthScience is paving the way for a sustainable future in clinical research.

About TFS HealthScience
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions.

The post TFS HealthScience Earns EcoVadis Silver Rating, Placing in Top 8% for Sustainability Excellence appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Portugal has experienced two consecutive years of double-digit growth in company-sponsored clinical trials. Portugal has become a highly attractive country for clinical research by creating a modern network of centers of excellence, experienced research teams, and optimal infrastructure.

“We are excited to grow our footprint in Europe with the opening of our office in Portugal,” said TFS HealthScience CEO Bassem Saleh. “This expansion allows us to have higher speed and agility in this region when deploying clinical resources, reaching patients, and helping our partners bring life-saving therapeutics to market faster. It offers local Biopharma direct access to TFS global capabilities.”

The opening of the Lisbon office aligns with the company’s growth plans as it continuously expands into new markets, enabling customers’ global access to clinical research solutions and development. In-country expertise and regional resources are valuable when working directly on projects or providing strategic resourcing to our customers.

“Most in our industry utilize Spanish affiliates or offices for their Portuguese operations. Our established history of working in Spain and a unique operational footprint in both countries gives TFS leadership in this geographic area,” said Vice President of Strategic Resourcing Solutions (SRS) Hanna Sandvall.

TFS HealthScience’s research and operations in Portugal will remain focused on its specialty therapeutic areas of dermatology, immunology and inflammatory disease, hematology and oncology, internal medicine and neuroscience, and ophthalmology.

About TFS HealthScience
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions.

The post TFS HealthScience Celebrates Grand Opening of Lisbon Office with Ribbon Cutting, Amid Growing Customer Demand appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

“2023 continues to be a year of growth for the company as we announce our formal expansion into Israel,” said Head of Clinical Development Solutions at TFS HealthScience Luke Gill. “We are confident that this expansion will bring immense value to our clients and ultimately support the development of more lifesaving therapies.”

Israel is a growing pharmaceutical and biotech hotspot and the preferred partner of companies in the Middle East. It is in the top 20 countries for registered pharmaceutical-sponsored clinical studies worldwide. Additionally, Israel has 1.5 to 3 times more frequent decentralized clinical trial components than the global average.

“We are thrilled for our CRO team to formally join TFS HealthScience following our six-year relationship as the company’s vendor in the Middle East,” said CEO and Co-Founder of GCP Ahuva Koren. “This formalized agreement will strengthen the connection of our client’s development research with some of the largest clinical research markets, including Europe and the U.S.”

This agreement will further grow TFS HealthScience’s expertise in the specialty therapeutic areas of ophthalmology, oncology and hematology, dermatology, immunology and inflammatory disease, and internal medicine and neuroscience.

About TFS HealthScience
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment, and strategic workforce management solutions.

About GCP Clinical Studies
GCP was founded in 2002 by Yossi Bornstein and Ahuva Koren as a clinical trials education company, later expanding to become Israel’s leading full-service Contract Research Organization (CRO). The company delivers successful clinical trial management solutions across a wide range of therapeutic areas for pharmaceuticals and medical devices. The people and projects of GCP’s CRO business will transition to TFS HealthScience, and its respected training facility will remain with GCP, which is part of the Shizim Group.

The post TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Bringing more than 15 years of business development and leadership experience within the life sciences sector, Sandvall will support the development and execution of customizable resourcing and talent management strategies and further strengthen the company’s executive team, which recently welcomed a highly experienced HR and talent leader Patrik Dursand as Chief People Officer. In this role, Sandvall will also coordinate with the TFS Clinical Development Services (CDS) to deliver full-service clinical development programs and services that best serve pharmaceutical and biotechnology companies.

Sandvall served in senior leadership and business development roles at several international companies. A former senior executive at Randstad, the world’s largest human resources services company, she directed the organization’s life sciences and engineering segment, managing over 350 supervisors and specialists while also contributing to the company’s profitability and growth. She was previously CEO and sales manager of LabRum, where she directed a turnaround that brought the Swedish company back to profitability. Significantly, Sandvall has extensive experience in consulting relationships supporting the life sciences industry and earned a Master of Science in chemical engineering at Lund University.

“Hanna brings considerable leadership and client-focused experience needed to extend the growth we are facing within Strategic Resourcing Solutions,” said TFS HealthScience CEO Bassem Saleh, Ph.D. “As the biopharmaceutical sector continues to multiply, the SRS team has helped position the company for continued international expansion by providing the essential resources needed to fuel the industry’s progression. Hanna’s unique and respected perspective to our operations will be of great value, building on the strong foundations we have in place from our 26 years of business.”

The international footprint and scale of the TFS HealthScience operation created a compelling opportunity, Sandvall said. “TFS HealthScience is large enough to have a long-term, positive impact on both pharma and biotech as well as human health,” she said. “Yet the company is nimble enough to remain flexible and offers short paths from decision to positive action.”

Team-based success was an important priority in her previous management roles, Sandvall said, adding that her previous achievements were accomplished with “high employee satisfaction and great collaboration. The key success factors that I hope to bring with me include the ability to create commitment, trust, and transparency among team members,” she added.

About TFS
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through two strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process, and Strategic Resourcing Solutions (SRS), which offers expert insourcing, targeted recruitment services, and strategic workforce management solutions.

TFS SRS has become one of the fastest-growing divisions at TFS HealthScience. The division provides customized global resourcing solutions that enable organizations to manage clinical trials with greater efficiency, quality, and flexibility. TFS SRS offers recruitment services for short- and long-term resourcing needs, deploying a global network with contacts in all clinical phases and therapeutic areas. Experienced recruiters identify talent for clinical development functions at all seniority levels through an international network of screened and qualified professionals. Key functions include clinical operations, project management, pharmacovigilance, biometrics, regulatory affairs, study site coordination, medical writing, and quality assurance.

The post New VP, Hanna Sandvall, Takes Helm for TFS HealthScience’s Strategic Resourcing Solutions appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Ophthalmology is a rapidly growing field of medicine, with novel innovations and cutting-edge treatments for sight-threatening diseases. A recent study published in The Journal of American Medicine found a 203% increase in funding for ophthalmology research from 2014 to 2020. Additionally, the worldwide ophthalmology drug market is expected to reach $60.3 billion by 2028, an increase of 6.4% from 2021 figures.

“We are proud to partner with Appletree as we continue to provide our clients with in-depth, comprehensive knowledge and therapeutic expertise, particularly in the field of ophthalmology,” said CEO of TFS HealthScience, Bassem Saleh. “This acquisition, and others in the pipeline, are a clear indicator of the growth and success of TFS. The partnership with Appletree will have a measurable impact on better treatments for patients and company growth, establishing a new presence in Switzerland and additional presence in Poland, Belgium, Hungary, and the U.K.”

The strategic acquisition of Appletree will complement TFS HealthScience’s mission to be a market leader in ophthalmology research. In a targeted business shift toward ophthalmology expertise, the company launched its elite site network initiative and site liaison services, which will shift the industry’s approach to ophthalmology clinical trial delivery.

“Today is a significant milestone for our company as we finalize our first acquisition in Ophthalmology, establishing clear leadership in a niche industry where expertise is highly valued, as clinical trials and strategy for ophthalmology indications are held to specific rules and regulations,” said VP of TFS HealthScience’s Ophthalmology Business Unit, Marcia Swank.

The two companies will now offer clients complimentary and expanded service offerings, including a specialized therapeutic focus in ophthalmology with an increased global footprint.

“We are thrilled to be joining the TFS HealthScience family,” said President and CEO of Appletree, Georg Mathis. “As one of the primary clinical service providers in Europe with in-depth knowledge of the complex medical devices and ophthalmology industry, we are prepared to exceed the expectations of our clients and patients.”

Appletree CI Group was founded in 2013 following the merger of Clinical Investigations and Appletree AG. The company is focused on five primary business areas; in addition to ophthalmology and medical devices, they have expertise in the fields of dermatology, pediatric trials, and regulatory affairs.

About TFS
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process, Strategic Resourcing Solutions (SRS), which offers expert insourcing and targeted recruitment services, and Functional Services (FSP), to provide customers with strategic workforce management solutions.

TFS HealthScience Ophthalmology has been the CRO of choice for more than 65 biotechnology and pharmaceutical clinical research projects in 24 countries and has an established presence in over 600 sites globally for clients ranging from industry leaders to early-stage companies and private practitioners, covering a variety of ocular pathologies from anterior to posterior segments.

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com.

About Appletree CI Group
Appletree CI Group is an expert niche CRO and global regulatory affairs service provider with track records in ophthalmology and medical device investigations. We are present in 11 European countries and have over 30 permanent staff. By having an in-depth understanding of local cultures and customs, as well as experience with national regulations we are able to facilitate your clinical development and regulatory projects.

Media Contact  

Emma Primon 
Executive Director, Marketing & Communications
+1 (908) 331.5463
Email

The post TFS HealthScience Acquires Appletree CI Group, Expanding Expertise in Ophthalmology and Medical Devices for Improved Patient Impact appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.

Based at the Lund headquarters, Darsund will report to CEO Bassem Saleh. “I am thrilled to welcome Patrik to the TFS team as our Chief People Officer,” said Saleh. “Our people are our biggest asset, and I am confident that his values-driven and inclusive approach to leadership will make an excellent addition to our executive team and have a positive impact on our global organization and corporate culture.”

An accomplished human resources executive, Darsund most recently served as a senior leader for human resources business partnering at the world’s leading wind turbine manufacturer, Vestas. With a history of supporting employees, leaders, and management teams in building high-performing cultures, his immediate focus will be on strengthening the cultural ties that characterize the TSF global team.

“I was drawn to TFS as an organization that puts a great deal of focus on employee experience and culture,” says Darsund. “I am excited to help drive the company forward with my immediate priorities being to meet and engage with our team members in addition to establishing the direction of the global HR function as we move into a period of meaningful growth.”

About TFS
TFS HealthScience is a global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: Clinical Development Services (CDS), which provides full-service support at all stages of the clinical development process, Strategic Resourcing Solutions (SRS), which offers expert insourcing and targeted recruitment services, and  Functional Services (FSP), to provide customers with strategic workforce management solutions. Detailed information about TFS and its business offerings can be obtained through www.tfscro.com

The post Patrik Darsund Joins TSF HealthScience as Chief People Officer to support the continued growth of the organization appeared first on TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO.